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The U.S. National Research Council (NRC) report on ‘‘Toxicity
Testing in the 21st century’’ calls for a fundamental shift in the
way that chemicals are tested for human health effects and
evaluated in risk assessments. The new approach would move
toward in vitro methods, typically using human cells in a highthroughput context. The in vitro methods would be designed to
detect significant perturbations to ‘‘toxicity pathways,’’ i.e., key
biological pathways that, when sufficiently perturbed, lead to
adverse health outcomes. To explore progress on the report’s
implementation, the Human Toxicology Project Consortium
hosted a workshop on 9–10 November 2010 in Washington, DC.
The Consortium is a coalition of several corporations, a research
institute, and a non-governmental organization dedicated to
accelerating the implementation of 21st-century Toxicology as
aligned with the NRC vision. The goal of the workshop was to
identify practical and scientific ways to accelerate implementation
of the NRC vision. The workshop format consisted of plenary
presentations, breakout group discussions, and concluding commentaries. The program faculty was drawn from industry,
academia, government, and public interest organizations. Most
presentations summarized ongoing efforts to modernize toxicology
testing and approaches, each with some overlap with the NRC
vision. In light of these efforts, the workshop identified recommendations for accelerating implementation of the NRC vision,
including greater strategic coordination and planning across
projects (facilitated by a steering group), the development of
projects that test the proof of concept for implementation of the
NRC vision, and greater outreach and communication across
stakeholder communities.
Key Words: toxicity testing in the 21st century; safety
assessment; in vitro alternatives; National Research Council.

THE NATIONAL RESEARCH COUNCIL VISION:
PATHWAYS TO IMPLEMENTATION

The 2007 U.S. National Research Council (NRC) report titled
‘‘Toxicity Testing in the 21st century: A Vision and a Strategy’’
(NRC, 2007) was the focus of a series of forum articles in
Toxicological Sciences (Andersen and Krewski, 2009; Bus and
Becker, 2009; Boekelheide and Campion, 2010; Chapin and
Stedman, 2009; Cohen Hubal, 2009; Hartung, 2009; Holsapple
et al., 2009; MacDonald and Robertson, 2009; Meek and Doull,
2009; Walker and Bucher, 2009). The series concluded with
a plea for the toxicology community to move from discussion of
the NRC report to action on its implementation (Andersen and
Krewski, 2010). In this spirit, the Human Toxicology Project
Consortium (http://htpconsortium.wordpress.com/about-2/) organized a workshop focused on ways to accelerate implementation
of the NRC vision for toxicity testing and risk assessment. The
Consortium is a coalition of several corporations, a research
institute, and a non-governmental organization, focused on
making the NRC vision a reality. This paper summarizes dialog
from the workshop and several key recommendations for moving
forward specifically with the NRC vision.
The NRC report (published in its entirety in Krewski et al.,
2010) calls for a fundamental shift in the way that chemicals
are tested for human health effects and are evaluated in risk
assessments. The proposed approach would decrease the
current reliance on animal studies and move toward in vitro
methods, typically using human cells in a high-throughput
context. The in vitro methods would be designed to detect
significant perturbations to ‘‘toxicity pathways,’’ i.e., key
biological pathways that, when sufficiently perturbed, lead to
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THE HUMAN TOXICOLOGY PROJECT CONSORTIUM

Before turning to the results of the workshop, we provide
a few more details on the Human Toxicology Project

Consortium. The Consortium seeks to help catalyze the
prompt, global, and coordinated implementation of a mode of
action approach to the risk assessment of chemicals as
proposed in the NRC vision. Specifically, the Consortium
promotes (1) the establishment and implementation of an
international research roadmap (including case studies of
prototype pathways to establish proof of principle), (2)
appropriate legislative, appropriations, and regulatory changes
necessary to advance the development and implementation of
the new methodology, and (3) greater appreciation of the need
for a prompt and global transformation to the new paradigm
among diverse stakeholders. The Consortium currently has
several members and partners. (Consortium members currently
include corporations [Dow, DuPont, ExxonMobil, Johnson &
Johnson, L’Oréal, Procter & Gamble, and Unilever], a research
institute [the Hamner Institutes for Health Sciences], and an
animal protection organization [The Humane Society of the
United States] and its affiliates [Humane Society Legislative
Fund and Humane Society International]. The Consortium has
partnered with the Johns Hopkins Center for Alternatives to
Animal Testing [CAAT], the ILSI Health and Environmental
Sciences Institute [HESI], and Toxicology Excellence in Risk
Assessment [TERA].)

THE WORKSHOP

The workshop format consisted of plenary presentations,
breakout group discussions, and concluding commentaries,
with ample time for questions and answers interspersed
throughout the 2-day event. The speakers and session chairs
were drawn from industry, academia, government, and public
interest organizations. The agenda and slides from the presentations are available online (http://htpconsortium.wordpress.com).
Current Efforts
Most of the plenary presentations focused on ongoing
efforts. They illustrated the diversity of projects currently
underway to advance 21st-century toxicology in the United
States and the European Union (EU) through not only research
but also conceptual development, coordination, advocacy, and
regulatory implementation initiatives (Table 1). These projects
include efforts by various sectors, including government (e.g.,
Tox21 in the United States and AXLR8 in the EU), industry
(e.g., Unilever and Procter & Gamble), academia (e.g., the
Trans-Atlantic Think Tank on Toxicology), and multistakeholder consortia (e.g., HESI’s Risk21 Project).
These projects seek to expand the frontiers of 21st-century
toxicology by harnessing advances in modern science and
technology. The efforts are diverse, each with its own goals and
aims (Table 1), as well as project management and funding.
Consequently, they overlap to varying degrees with the NRC
vision itself. However, it was apparent that no one project fully
captures all the elements of the NRC vision and it is arguable as
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adverse health outcomes. The results from this in vitro testing
would then be interpreted with the aid of new tools and
approaches, including systems biology and computer-based
modeling, and incorporated directly into risk assessment
(Boekelheide and Andersen, 2010; Bhattacharya et al., 2011).
A feature of the NRC vision that has received less attention
is its shift away from the prevailing emphasis on risk assessment
based on high-dose observations to a safety-based paradigm
based on pathway perturbations (Andersen and Krewski, 2010).
The new pathway-based approach would be used to identify the
doses below which an exposure is not likely to result in harm.
The research and development necessary to fully realize the
NRC vision was expected to take one to two decades to develop
pathway assays and the suite of tools for interpreting these
results to ensure safety (NRC, 2007).
This new framework is expected to have several advantages
over current practice (NRC, 2007), including a more relevant
scientific foundation for human health risk assessments, lower
costs and shorter duration of testing and assessment, broader
coverage of chemicals, health effects, life stage targets and
mixtures (given the new tools’ higher throughput, lower cost,
and shorter duration), and cumulative reductions in animal
usage as the new models and approaches gain scientific and
regulatory acceptance.
The NRC vision has led to an emphasis on ‘‘21st-century
toxicology’’ consistent with the report’s general theme of
harnessing modern advances in biology and technology for
use in toxicity testing. Several comprehensive initiatives are
underway to modernize toxicology; many of these were featured
at the workshop. Although each of these diverse efforts reflects
its own priorities and mandates, they are clearly relevant to the
NRC vision and are important complementary activities.
In light of the call to move from discussion of the NRC
report to action on its implementation (Andersen and Krewski,
2010), the Human Toxicology Project Consortium believed the
time was right for interested stakeholders to take stock of
relevant current and planned initiatives and to explore potential
ways to accelerate progress toward the use of dose-response
information, computational toxicity pathway models, and
in vitro-in vivo extrapolation for guiding human safety assessments from in vitro toxicity testing assays. Consequently, the
Consortium hosted an open workshop titled ‘‘Accelerating
Implementation of the NRC Vision for Toxicity Testing in the
21st Century’’ on 9–10 November 2010 at Gallaudet University
in Washington, DC. The workshop was designed to explore
ongoing and planned initiatives in North America and Europe
related to the NRC vision, evaluate progress to date, and identify
the highest priority needs to accelerate progress.
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TABLE 1
Workshop Presentations on Current Efforts Related to the Implementation of the NRC Vision for Toxicity Testing in the 21st Century
Workshop presenter

Project

Research and development efforts
Raymond Tice
Tox21

Description

U.S. NIH Chemical Genomics
Center, Environmental
Protection Agency, National
Institute of Environmental
Health Sciences, Food and
Drug Administration

Developing ultra
high-throughput testing
systems and bioinformatic
tools to assess the biological
activity of chemicals on cells
in order to predict in vivo
toxicities
Developing high-throughput
testing systems to predict
potential toxicity and to cost
effectively prioritize the
thousands of chemicals that
need toxicity testing
Developing high-throughput
and high-content assays to
move from empirical to
predictive toxicology
Developing nonanimal
methods and a systems
biology approach to assure
consumer safety with respect
to skin sensitization
Developing the tools and
approaches to explore
individual ‘‘toxicity
pathways’’ as case studies

Robert Kavlock

ToxCast

U.S. Environmental Protection
Agency

Maurice Whelan

In Vitro Assay Technologies
for the Development of
Alternative Methods

Cameron MacKay

Skin Sensitization
Programme

Institute for Health and
Consumer Protection, Joint
Research Center, European
Commission
Unilever

Mel Andersen

Pilot Projects

George Daston

Systems Approach

Advocacy efforts
Martin Stephens

Coordination efforts
Horst Spielmann

Currently focusing on rapid
screening for hazard
identification

Currently focusing on rapid
screening for prioritization of
animal testing

Scaling up in vitro assays for
high-throughput systems to
meet a variety of challenges
Focusing on risk assessment

Pursuing the NRC vision by
proof of concept with datarich chemicals targeting wellcharacterized pathways

Developing a systems approach
to predictive toxicology
through the application of
cheminformatics, dynamic
modeling, and
toxicogenomics

Employing sophisticated tools
and approaches without
explicit mapping to the NRC
vision

Center for Alternatives to
Animal Testing (United
States and EU) and Utrecht
University
ILSI Health and Environmental
Sciences Institute

Spearheading conceptual
developments to help
promote the transition to
21st-century toxicology
A multi-sector collaboration
developing conceptual
frameworks for applying the
new tools to quantitative risk
assessment

Pioneering ‘‘evidence-based
toxicology’’ as a means of
quality assurance of new
methods
Basing its efforts on a variety of
frameworks, including the
NRC vision

Human Toxicology
Project

Human Toxicology Project
Consortium

Advocating for an accelerated
implementation of the NRC
vision

Advocating for a ‘‘Human
Toxicology Project’’ on a par
with the Human Genome
Project

AXLR8

European Commission

Providing tools and
opportunities for increased
networking, information
exchange, problem solving,
strategic planning, and
collaboration among
a variety of scientific
disciplines and stakeholder
groups

Accelerating the transition
toward ‘‘21st century’’
approaches in toxicology and
risk assessment

Conceptual development efforts
Thomas Hartung
t4

Tim Pastoor

The Hamner Institutes for
Health Sciences in
partnership with the Human
Toxicology Project
Consortium
Procter & Gamble

Notes regarding the NRC vision

Risk21
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TABLE 1—Continued
Workshop presenter

Project

Regulatory implementation efforts
Jack Fowle
Incorporating 21stcentury toxicology

Lead organization(s)

U.S. Environmental
Protection Agency

Notes regarding the NRC vision

Incorporating ‘‘21st-century’’
toxicology into its regulatory
practices in the short-,
medium-, and long-term, as
developments permit.

Putting the NRC vision into
regulatory practice as
research and development
efforts bear fruit (the agency
had funded the NRC’s work
on the vision report)

Recommendations
Strategic planning, coordination, and a steering group. As
was evident from the presentations on the first day of the
workshop, many projects are currently expanding the frontiers
of 21st-century toxicology. They overlap to varying degrees
with the NRC vision. One way to achieve better collective
focus and progress on the goals noted in the NRC report would
be to enhance any existing coordination and planning among
those projects that overlap most heavily with the NRC
proposal. To help provide the necessary leadership for this,
the workshop participants recommended that a ‘‘steering
group’’ be established. This group could comprise the leadership of the relevant projects along with representatives from
interested stakeholder communities, including risk assessors.
Some level of strategic planning and coordination is already
evident in several projects presented or discussed at the
workshop. For example, Tox21 (http://htpconsortium.files.
wordpress.com/2010/11/tice.pdf) is a collaboration across four
federal entities in the United States, and Risk21 (http://www.
hesiglobal.org/i4a/pages/index.cfm?pageid¼3492) is a multistakeholder collaboration. Nonetheless, these are examples of
planning and coordination within a given project. Planning and
coordination across projects is less common. AXLR8 (http://
axlr8.eu/) is a coordination project addressing relevant EU-funded
efforts, and its scientific panel includes scientists based outside
the EU. The Molecular Screening Project, which was mentioned
at the workshop, promotes collaboration across relevant
projects of member states of the Organization for Economic
Cooperation and Development (http://www.oecd.org/document/
29/0,3746,en_2649_34373_34704669_1_1_1_1,00.html).
Nonetheless, there was a strong sense at the workshop that
greater cooperation across relevant projects was the key to
speeding up the NRC vision. Where appropriate, such
cooperation should span research sectors (government, academia, and industry) and international borders. It could entail
collaboration on the generation of new data using pathway
testing and targeted testing, as well as on the interpretation of
what the data mean in a human health context. Both the testing
assays and data interpretation tools will require new methodological approaches.
Data sharing surfaced as another way to facilitate coordination
and collaboration. Data repositories should be developed for
others to mine and interpret, as well as to factor into their
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to whether they do so collectively. Many of these projects
currently do not feature the NRC vision’s proposed interpretative
tools for dose-response and in vitro-in vivo extrapolations for
risk assessment and the elucidation of regions of exposures that
are predicted to be without adverse effects.
Similarly, much of the current activity in 21st-century
toxicology is at least temporarily anchored in the prevailing
conceptual framework centered on high-dose animal studies and
hazard identification, e.g., using high-throughput in vitro testing
as a means of more rapidly prioritizing chemicals for follow-up
testing in animals. In contrast, the NRC proposal would replace
this framework with a new platform of safety-based risk
assessments centered on pathway testing in human cells.
At the workshop, a framework was offered to categorize
efforts to promote 21st-century toxicology with respect to how
they advance the NRC vision. One of the three overlapping
categories in this framework is ‘‘laissez-faire,’’ in which efforts
in academic research labs and elsewhere make incremental
contributions and the field develops organically over time.
Another is ‘‘indirect,’’ in which the new tools and approaches
are applied initially as enhancements within the prevailing
hazard identification framework centered on animal studies, and
perhaps at later stages, would evolve toward the NRC safety
assessment framework centered on pathway studies. The third
approach is ‘‘direct,’’ in which the new tools and approaches are
applied directly in an attempt to develop proof of concept
examples to show the NRC vision in action.
Ongoing efforts to advance 21st-century toxicology follow
primarily the laissez-faire and indirect approaches. These
orientations are hardly surprising given the formidable
scientific, technical, and regulatory challenges in charting
a direct path to the NRC framework. At the workshop itself,
most of the plenary presentations described projects in the
indirect camp (Table 1).
From the perspective of those seeking a prompt, global
implementation of the NRC vision for 21st century toxicology,
including the Human Toxicology Project Consortium, the
direct approach remains most appealing. However, enthusiasm
for rapid action toward the NRC goal is tempered by the fact
that current initiatives represent a diverse landscape with many
stakeholders. Coalescing these disparate camps around a more
common vision for rapid action presents both challenges and
opportunities.

Description

IMPLEMENTING 21ST CENTURY TOXICOLOGY

Support for pilot projects on the NRC vision as a way
forward. Among its goals, the Human Toxicology Project
Consortium seeks funding for several ‘‘direct approach’’
projects to evaluate the steps required to use toxicity pathway
assay results for human health risk assessment. These
projects are intended to jumpstart implementation of the
NRC vision. An example of such projects is now underway at
The Hamner Institutes for Health Sciences (http://www.thehamner.org/tt2). This research (Andersen, 2011), pursued
with endorsement from the Consortium, directly probes the
NRC vision through case studies with data-rich prototype
compounds that are known to target specific toxicity
pathways. This program was presented in a plenary session
and discussed in a breakout session. The first studies on these
prototype pathways are underway with support from Dow,
ExxonMobil, Unilever, and the American Chemistry Council. The project involves the design and validation of human
cell or tissue assays to examine adverse effects as envisioned
by the NRC. These techniques are intended to identify and
evaluate key toxicity pathway perturbations (Boekelheide and
Andersen, 2010; NRC, 2007) and to create the knowledge base
required to apply in vitro pathway assay test results, bioinformatic analysis of pathway function, and in vitro-in vivo
extrapolation tools to human health risk assessment. Success
with these prototypes could refine aspects of the NRC vision and
pave the way for more rapid widespread application of tools
with more diverse pathways.
Workshop participants were in general agreement that a pilot
project approach to implementing the NRC vision could
augment other existing approaches and should be pursued as
one of the options to move the NRC vision forward. There was

a strong feeling that any ‘‘direct’’ project, including that
proposed by the Hamner Institutes, should also seek advice
from regulators up front, have clear human relevance, and
focus on relevant exposures in a risk assessment context.
Some participants, however, cautioned against putting too
many eggs in a single basket, believing strongly that approaches
that move progressively to a systems toxicology focus or that
more directly investigate mechanisms of toxic end points
(Daston and Naciff, 2010; Rusyn and Daston, 2010) will likely
also be essential in the long-term realization of the NRC vision.
The discussions about direct versus indirect and laissez-faire
approaches highlighted the different motivating factors between
these various options. The evolutionary path via indirect and
laissez-faire approaches was attractive to some participants
because the present knowledge base for systems toxicology does
not yet appear to provide unequivocal guidance about the
optimum approaches. In addition, there was concern that moving
too quickly with a single direct option could impede acceptance
of new technologies if the direct approach failed to fulfill
expectations. On the other hand, the direct approach could
implement current knowledge with prototypes and evaluate
strengths and weaknesses of current systems toxicology tools for
more immediate implementation. There is clearly a healthy
tension between incremental advancement of a variety of tools
with natural selection of preferred methods (a hallmark of the
laissez-faire approach) versus a direct approach that tries to focus
on a preferred path forward (e.g., proof of concept of an explicit
interpretation of the NRC vision) and make necessary course
corrections as work progresses.
Notwithstanding expressions of support for pilot projects
and other direct approaches as a means of accelerating the
vision, many participants underscored the need for a mix of
approaches, given the inevitable uncertainties over the best path
forward. Implementation is likely to be slower with this mix
rather than with a direct approach, but a unified direct approach
would entail the challenge of developing more of a consensus
about the best path forward. Moreover, many participants felt
that the indirect approach to implementation was a practical
necessity for regulators, for both confidence building and
bridging between the current and new approaches for toxicity
testing and risk assessment.
Communication. Reinventing toxicity testing and risk
assessment requires a high level of communication among
those carrying out the work, but perhaps as importantly,
considerable outreach and discussion with interested stakeholders, including relevant congressional decision makers and
advocates for public health, environment protection, and
animal protection. This outreach should happen early in the
process by seeking input and ‘‘buy-in.’’ Stakeholders should
not be presented with finished products and only then asked for
their support.
For these purposes, a communication strategy was also
recommended. The communication that has taken place to date
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research plans. The Environmental Protection Agency’s (EPA’s)
ToxRefDB (Toxicity Reference Database) contains study design
and effect information on thousands of in vivo studies of
hundreds of chemicals (http://www.epa.gov/ncct/toxrefdb/).
Obtaining data from the pharmaceutical industry—with its
direct focus on human biology—may also accelerate implementation of 21st century chemical risk assessment.
This coordination and planning could focus systematically
on each of the NRC vision components—in silico approaches
for chemical characterization, toxicity pathway testing, targeted
testing, and dose-response and extrapolation modeling—and
link these together. The planning should ensure some level of
balance among the vision components being implemented. In
the United States, for example, a doubling in funding of the
Tox21 initiative as currently designed would reportedly
saturate the ability of the project to deal with the increased
volume of data. Thus, there must be a clear recognition that
increased capacity to generate data must be accompanied by an
increased capacity to process and utilize the information for
chemicals management. Ultimately, the goal of strategic
planning and coordination across projects is to accelerate
application of the new technology in a regulatory context.
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DISCUSSION

The NRC vision was designed to modernize current
toxicity testing. Animal-based methods are low throughput
and do not sufficiently reflect advances in modern biology or
human responses to chemical exposure (NRC, 2006). The
resulting vision has received broad support. Collins et al.
(2008) elaborated on it in a high-profile perspective in
Science, in which they proposed ‘‘a shift from primarily
in vivo animal studies to in vitro assays, in vivo assays with
lower organisms, and computational modeling for toxicity
assessments.’’
The workshop generated a number of recommendations for
accelerating implementation of the NRC vision. These centered
on the expected value of (1) coordination and planning across
relevant projects, facilitated by a steering group, (2) more direct
approaches to implementation the NRC vision to supplement
current research efforts, and (3) greater communication across
stakeholder communities regarding the NRC vision and its
promise.
Coordination and Planning
The 2-day workshop was not the forum to elaborate the
details of the proposed steering group, such as its size,
composition, and governance, nor debate whether steering
group was the most appropriate name for the group. Indeed, in
subsequent discussions, concerns have been raised that the
label steering group might imply that the ad hoc body would
have executive authority to dictate the future course of events.
The Human Toxicology Project Consortium organizers of the
November workshop have provisionally settled on ‘‘Implementation Group’’ as a more apt name that is more reflective of
the fact that the group would not be empowered to mandate
how individual projects should be run. (For the purpose of this
summary, however, we retain the steering group label.) Any
recommendations developed by the group would be just
that—recommendations. Nonetheless, a properly constituted
motivated group could have a catalyzing influence on the
course and pace of developments.
The NRC report discussed the possibility of a stand-alone
institute being established to implement its proposed vision.

The institute would be roughly on the scale of the U.S.
National Toxicology Program. Such a dedicated implementation mechanism would foster—virtually by definition—a high
degree of coordination and strategic planning. However, no
such institute has been created for this purpose, nor does one
seem likely in the near future. Nonetheless, a steering group, if
implemented, could markedly increase the level of collaboration across projects and thereby accelerate progress.
One speaker (Andrew Rowan, Humane Society International) proposed a ‘‘big biology’’ project along the lines of the
Human Genome Project to accelerate implementation of the
NRC vision. This effort was termed the ‘‘Human Toxicology
Project’’ (see http://htpconsortium.files.wordpress.com/2010/
11/rowan.pdf). The workshop also included a presentation by
Christopher Austin (National Institutes of Health) on lessons
learned from the Human Genome Project that would need to be
carefully considered if a large scale project were to be considered
as an implementation strategy (see http://htpconsortium.files.
wordpress.com/2010/11/austin.pdf). These key lessons (Collins
et al., 2003) were: build the best teams, ensure the process is
science-driven, meet managerial challenges, seek international
participation, establish explicit milestones and quality assessments, strive for technological advancement that can accelerate
the project, release data rapidly to demonstrate the project’s value
to the community, and address social consequences as part of the
project.
Many of these lessons speak to the crosscutting issues of
coordination and planning. The Human Toxicology Project
Consortium believes that a Human Genome Project-type effort,
even if fairly decentralized, should be marshaled to realize the
NRC vision. The themes and recommendations that emerged
from this workshop can help guide such an effort.
A central challenge for a steering group should be to hasten
the application of the new tools and approaches beyond
screening and priority-setting, to hazard identification and doseresponse analysis—two key components of risk assessment.
Similarly, the steering group should also expedite the use of the
new methods to diverse risk contexts (NRC, 2007), not all of
which demand assays that are high-throughput. Collaboration
between the ultimate users of the technology (risk assessors)
and the developers will help clarify regulatory expectations and
facilitate timely application of the new techniques (Dellarco
et al., 2010), allowing decision makers to use the next
generation of tools and approaches to make more informed
and efficient responses to diverse public health concerns faced
by regulators, industry, and the public (NRC, 2007).
Such cross-sector collaboration is already a feature of the
HESI Risk21 project (http://www.hesiglobal.org/i4a/pages/
index.cfm?pageid¼3492), in which the elements of the NRC
vision for toxicity testing in the 21st century have been
integrated into the project objective to create a systematic
approach for incorporating novel approaches and technologies,
as available and when appropriate, to aid in advancing human
health assessments.
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has been largely within the scientific community, researcher to
researcher. Wider outreach has not been a priority. The U.S.
EPA’s Pesticide Program Dialogue Committee (http://www.
epa.gov/pesticides/ppdc/) was mentioned as an existing
structure that may be instructive in this regard. A communication strategy could be developed by interested stakeholders
perhaps in consultation with the steering group (should one be
formed). The strategy should convince interested parties,
including the public at large, that the new approach reduces
uncertainties in the risk assessment process, compared with the
current approach.
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Concluding Remarks
Implementation of the NRC vision should be seen as an
iterative progressive transformation, not an all-or-nothing switch
that will take place 20 years from now. In this context,
stakeholders should be attuned to opportunities to ensure
incorporation of emerging 21st-century toxicology tools and
approaches into regulatory decisions that are on the horizon. For
example, efforts are underway to revise the Toxic Substances
Control Act (TSCA) in the United States and biocides regulation
in the EU. The introduction of the tools and data derived from
the new approaches could be accelerated by supportive language
placed in revisions to these existing statutes. A recent paper
(Locke and Myers, 2010) discussed the challenges and
opportunities of implementing the NRC vision and strategy for
toxicity testing that will arise under the key provisions of TSCA,
concluding that TSCA, as currently written, creates a sufficient
legal foundation for the NRC vision.
In summary, the Human Toxicology Project Consortium
workshop illustrated the diversity of projects underway that are
advancing pathway-based approaches to toxicity testing, which
underpin the NRC vision for toxicity testing in the 21st
century. Workshop participants made several recommendations
for accelerating the implementation of this vision, including
enhancing collaboration across relevant projects via a steering
group, complementing existing efforts with more direct
approaches to implementing the NRC vision, and crafting
a communications strategy that reaches out to diverse stakeholders on the nature and benefits of implementing the new
paradigm. Policy-oriented stakeholders should be attentive to
opportunities to incorporate NRC vision-friendly provisions
into new or amended public policies.
These recommendations fall primarily in the realm of
science policy and not ‘‘hard science.’’ Nonetheless, they bear

quite heavily on the question of how soon the new science of
toxicology will be brought online. For this reason, we offer
them to the broad toxicology community as possibilities for
action.
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